About Adverum Biotechnologies
Adverum Biotechnologies is a company based in Menlo Park (United States) founded in 2006 was acquired by Lilly in October 2025.. Adverum Biotechnologies has raised $131.43 million across 9 funding rounds from investors including Lilly, SBIR and TCG Crossover. The company has 155 employees as of December 31, 2024. Adverum Biotechnologies has completed 1 acquisition, including Annapurna Therapeutics. Adverum Biotechnologies offers products and services including Ixo-vec. Adverum Biotechnologies operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Denali Therapeutics and Forge Biologics, among others.
- Headquarter Menlo Park, United States
- Employees 155 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adverum Biotechnologies, Inc.
-
Annual Revenue
$1 M-72.22as on Dec 31, 2024
-
Net Profit
$-130.93 M-7.22as on Dec 31, 2024
-
EBITDA
$-149.51 M-21.16as on Dec 31, 2024
-
Total Equity Funding
$131.43 M (USD)
in 9 rounds
-
Latest Funding Round
$127.8 M (USD), Post-IPO
Feb 05, 2024
-
Investors
Lilly
& 14 more
-
Employee Count
155
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Lilly
(Oct 24, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adverum Biotechnologies
Adverum Biotechnologies is a publicly listed company on the NASDAQ with ticker symbol ADVM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Adverum Biotechnologies
Adverum Biotechnologies offers a comprehensive portfolio of products and services, including Ixo-vec. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational treatment for wet AMD to sustain protein expression.
Unlock access to complete
Unlock access to complete
Leadership Team
26 people
Software Development Team
19 people
Product Management Team
6 people
Senior Team
5 people
Operations Team
4 people
Finance and Accounting
3 people
Human Resources and Administration
3 people
Data Analysis and Operations Team
3 people
Unlock access to complete
Funding Insights of Adverum Biotechnologies
Adverum Biotechnologies has successfully raised a total of $131.43M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $127.8 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $127.8M
-
First Round
First Round
(01 Oct 2012)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Post-IPO - Adverum Biotechnologies | Valuation |
investors |
|
| May, 2016 | Amount | Post-IPO - Adverum Biotechnologies | Valuation |
investors |
|
| Sep, 2014 | Amount | Post-IPO - Adverum Biotechnologies | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adverum Biotechnologies
Adverum Biotechnologies has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, SBIR and TCG Crossover. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital is provided to healthcare startups by Commodore Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adverum Biotechnologies
Adverum Biotechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Annapurna Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AAV-mediated gene therapies for rare diseases are developed.
|
2014 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Adverum Biotechnologies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adverum Biotechnologies Comparisons
Competitors of Adverum Biotechnologies
Adverum Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Denali Therapeutics and Forge Biologics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adverum Biotechnologies
Frequently Asked Questions about Adverum Biotechnologies
When was Adverum Biotechnologies founded?
Adverum Biotechnologies was founded in 2006 and raised its 1st funding round 6 years after it was founded.
Where is Adverum Biotechnologies located?
Adverum Biotechnologies is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Is Adverum Biotechnologies a funded company?
Adverum Biotechnologies is a funded company, having raised a total of $131.43M across 9 funding rounds to date. The company's 1st funding round was a Post-IPO of $10M, raised on Oct 01, 2012.
How many employees does Adverum Biotechnologies have?
As of Dec 31, 2024, the latest employee count at Adverum Biotechnologies is 155.
What is the annual revenue of Adverum Biotechnologies?
Annual revenue of Adverum Biotechnologies is $1M as on Dec 31, 2024.
What does Adverum Biotechnologies do?
Founded in 2006 and headquartered in Menlo Park, United States, gene therapy products for ophthalmologic conditions are developed by the company. The Ocular BioFactor platform employs adeno-associated virus vectors to deliver genes that produce therapeutic proteins. Pipeline programs, such as AVA-101, target wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion within the biotechnology sector.
Who are the top competitors of Adverum Biotechnologies?
Adverum Biotechnologies's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Adverum Biotechnologies offer?
Adverum Biotechnologies offers Ixo-vec.
Is Adverum Biotechnologies publicly traded?
Yes, Adverum Biotechnologies is publicly traded on NASDAQ under the ticker symbol ADVM.
How many acquisitions has Adverum Biotechnologies made?
Adverum Biotechnologies has made 1 acquisition, including Annapurna Therapeutics.
Who are Adverum Biotechnologies's investors?
Adverum Biotechnologies has 15 investors. Key investors include Lilly, SBIR, TCG Crossover, 5AM Ventures, and Commodore Capital.
What is Adverum Biotechnologies's ticker symbol?
The ticker symbol of Adverum Biotechnologies is ADVM on NASDAQ.